HBI Deals+Insights / M&A/IPOs
SK Capital Partners, a New York-based investment firm focused on life sciences, speciality materials, and ingredients, has acquired Swiss drug distribution company Swixx BioPharma for €1.5 billion (~US$1.73 bn). Specialised investment firm Bain Capital Life Sciences also joined SK Capital as a minority investor.





